Increased Risk of Cerebrovascular Adverse Events and Death in Elderly Demented Patients Treated With Atypical Antipsychotics: What's a Clinician to Do?

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Recent U.S. Food and Drug Administration (FDA) warnings of increased risk of cerebrovascular adverse events (CVAEs) and increased mortality with atypical antipsychotics in older patients with dementia have received considerable attention and resulted in black box warnings for this drug class. Clinicians who treat these patients have a challenging clinical dilemma. Behavioral problems in this patient group can be severe and can result in nursing home placement.​

J Clin Psychiatry 2005;66(8):1071-1071